{
    "startDate": "2020-01-01",
    "endDate": "2020-09-30",
    "year": "2020",
    "quarter": "Q3",
    "symbol": "CLBS",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 21156000
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 41258000
            },
            {
                "label": "Total assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 42019000
            },
            {
                "label": "Marketable securities",
                "concept": "MarketableSecurities",
                "unit": "usd",
                "value": 19113000
            },
            {
                "label": "Marketable securities",
                "concept": "MarketableSecurities",
                "unit": "usd",
                "value": 19113000
            },
            {
                "label": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 19,407,057 and 10,528,689 shares at September 30, 2020 and December 31, 2019, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 19000
            },
            {
                "label": "Prepaid and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 989000
            },
            {
                "label": "Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2020 and December 31, 2019, respectively",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Total liabilities",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 4532000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 694000
            },
            {
                "label": "Other long-term liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 351000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 458560000
            },
            {
                "label": "Accumulated other comprehensive (loss) income",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -12000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -420119000
            },
            {
                "label": "Noncontrolling interests",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -253000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 37487000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 37487000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 37487000
            },
            {
                "label": "Commitments and Contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 3076000
            },
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 3076000
            },
            {
                "label": "Treasury stock, at cost; 11,080 shares at September 30, 2020 and December 31, 2019",
                "concept": "TreasuryStockValue",
                "unit": "usd",
                "value": 708000
            },
            {
                "label": "Liabilities and Equity, Total",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 42019000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 1105000
            },
            {
                "label": "Total Caladrius Biosciences, Inc. stockholders' equity",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 37740000
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 4181000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 67000
            }
        ],
        "cf": [
            {
                "label": "Tax withholding payments on net share settlement equity awards",
                "concept": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
                "unit": "usd",
                "value": 148000
            },
            {
                "label": "Other assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": -387000
            },
            {
                "label": "Net proceeds from issuance of common stock",
                "concept": "ProceedsFromIssuanceOrSaleOfEquity",
                "unit": "usd",
                "value": 18715000
            },
            {
                "label": "Share-based compensation",
                "concept": "IssuanceOfStockAndWarrantsForServicesOrClaims",
                "unit": "usd",
                "value": 1090000
            },
            {
                "label": "Net cash provided by (used in) investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -8187000
            },
            {
                "label": "Prepaid and other current assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 174000
            },
            {
                "label": "Net cash provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 18567000
            },
            {
                "label": "Purchase of marketable securities",
                "concept": "PaymentsToAcquireMarketableSecurities",
                "unit": "usd",
                "value": 21819000
            },
            {
                "label": "Sale of marketable securities",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": 13646000
            },
            {
                "label": "Accretion on marketable securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": -172000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net cash used in operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -3256000
            },
            {
                "label": "Accounts payable, accrued liabilities and other liabilities",
                "concept": "clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
                "unit": "usd",
                "value": -2068000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationAndAmortization",
                "unit": "usd",
                "value": 46000
            },
            {
                "label": "Net increase in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": 7124000
            },
            {
                "label": "Purchase of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 14000
            }
        ],
        "ic": [
            {
                "label": "Total other income",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": 118000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 6346000
            },
            {
                "label": "Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -2719000
            },
            {
                "label": "Total operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 13699000
            },
            {
                "label": "Benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": -10872000
            },
            {
                "label": "Basic and diluted shares",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 14116000
            },
            {
                "label": "Less - net income attributable to noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
                "unit": "usd",
                "value": 10000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "General and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 7353000
            },
            {
                "label": "Net loss before benefit from income taxes and noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -13581000
            },
            {
                "label": "Operating loss",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -13699000
            },
            {
                "label": "Investment income, net",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": 118000
            },
            {
                "label": "Caladrius Biosciences, Inc. common stockholders (in usd per share)",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -0.19
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -2723000
            },
            {
                "label": "Available for sale securities - net unrealized (loss) income",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -14000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -2709000
            },
            {
                "label": "Comprehensive income attributable to noncontrolling interests",
                "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 10000
            },
            {
                "label": "Total other comprehensive (loss) income",
                "concept": "OtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -14000
            },
            {
                "label": "Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -2733000
            }
        ]
    }
}